Publications by authors named "Jennifer Totman"

Claim this Profile
C
Conformational-Design-Driven Discovery of EZM0414: A Selective, Potent SETD2 Inhibitor for Clinical Studies.
Joshua S Alford, John W Lampe, Dorothy Brach, Richard Chesworth, Kat Cosmopoulos, Jennifer Totman

ACS Med Chem Lett· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a First-in-Class Inhibitor of the Histone Methyltransferase SETD2 Suitable for Preclinical Studies.
John W Lampe, Joshua S Alford, P Ann Boriak-Sjodin, Dorothy Brach, Kat Cosmopoulos, Jennifer Totman

ACS Med Chem Lett· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.
Michael J Thomenius, Jennifer Totman, Darren Harvey, Lorna H Mitchell, Thomas V Riera

PLoS One· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor.
Lorna H Mitchell, P Ann Boriack-Sjodin, Sherri Smith, Michael Thomenius, Nathalie Rioux, Jennifer Totman

ACS Med Chem Lett· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis